29 April 2024 in Proceedings of the National Academy of Sciences
Determining the pathogenicity of hypertrophic cardiomyopathy–associated mutations in the β-myosin heavy chain ( MYH7 ) can be challenging due to its variable penetrance and clinical severity. This study investigates the early pathogenic effects of the incomplete-penetrant MYH7 G256E mutation on myosin function that may trigger pathogenic adaptations and hypertrophy. We hypothesized that the G256E mutation would alter myosin biomechanical function, leading to changes in cellular functions. We developed a collaborative pipeline to characterize myosin function across protein, myofibril, cell, and tissue levels to determine the multiscale effects on structure–function of the contractile apparatus and its implications for gene regulation and metabolic state. The G256E mutation disrupts the transducer region of the S1 head and reduces the fraction of myosin in the folded-back state by 33%, resulting in more myosin heads available for contraction. Myofibrils from gene-edited MYH7 WT/G256E human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) exhibited greater and faster tension development. This hypercontractile phenotype persisted in single-cell hiPSC-CMs and engineered heart tissues. We demonstrated consistent hypercontractile myosin function as a primary consequence of the MYH7 G256E mutation across scales, highlighting the pathogenicity of this gene variant. Single-cell transcriptomic and metabolic profiling demonstrated upregulated mitochondrial genes and increased mitochondrial respiration, indicating early bioenergetic alterations. This work highlights the benefit of our multiscale platform to systematically evaluate the pathogenicity of gene variants at the protein and contractile organelle level and their early consequences on cellular and tissue function. We believe this platform can help elucidate the genotype–phenotype relationships underlying other genetic cardiovascular diseases.
5 May 2026 in Communications Chemistry
Mutations in myosin alter its motor functions in diverse ways by affecting different structural and chemo-mechanical events. Multidisciplinary strategies can be used to understand how varying alterations in motor function converge to common phenotypes like hypercontractility and hypertrophic cardiomyopathy (HCM). We combined molecular dynamics (MD) simulations with protein biochemical and myofibril mechanical analyses to study the HCM-causing myosin variant G256E. MD simulations demonstrated that G256E induces structural changes that increase the work required to displace ADP.Mg2+ from actomyosin. Stopped-flow biochemical analysis demonstrated increased ADP affinity and decreased ADP release rate, and single myofibril mechanics analysis demonstrated increased force generation and reduced ADP sensitivity of the early, slow phase of relaxation. Together, these results demonstrate that slower ADP release from myosin during contraction is a significant contributor to pathological contractile nature of the G256E mutation. This study highlights the importance of detailed chemo-mechanical analysis of mutations associated with hereditary cardiac diseases.
29 October 2026 in bioRxiv
1. We recently reported that we could find no evidence of the biochemically-defined super relaxed (SRX) state in tissue-isolated HMM, as defined in the original mant-ATP displacement assay. This is consistent with theoretical predictions that any SRX state would have to be in thermal equilibrium with the disordered-relaxed (DRX) form of myosin heads. We repeat the assay here for isolated myosin, from different sources, in its monomeric form or in synthetic myosin filaments. No slow component of the displacement assay was observed, and we again conclude that there is no evidence for the SRX state for isolated myosins. This does not mean that there are no myosins in the ATPase-inhibiting Interacting Heads Motif (IHM) in our assays, just that any IHM is in rapid equilibrium with DRX heads. Mant-ATP displacement assays in the presence of the inhibitor Mavacamten or the activator 2’-deoxyATP (dATP) do provide evidence of an interaction between the two heads of myosin. In contrast, assays with myofibrils do provide evidence of two components in the mant-ATP displacement assay. We propose that these two components result from distinct populations of myosin within the sarcomere thick filament with different fractions of myosin in the IHM structural state.